FullText URL fulltext.pdf
Author Sakaeda, Kazuma| Sadahira, Takuya| Maruyama, Yuki| Iwata, Takehiro| Watanabe, Masami| Wada, Koichiro| Araki, Motoo|
Keywords antimicrobial resistance Escherichia coli urinary tract infections flomoxef ST131
Published Date 2023-03-06
Publication Title Antibiotics
Volume volume12
Issue issue3
Publisher MDPI
Start Page 522
ISSN 2079-6382
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © 2023 by the authors.
File Version publisher
PubMed ID 36978389
DOI 10.3390/antibiotics12030522
Web of Science KeyUT 000952995400001
Related Url isVersionOf https://doi.org/10.3390/antibiotics12030522
FullText URL fulltext.pdf
Author Sun, Jingkai| Lin, Wenfeng| Li, Chaoming| Ueki, Hideo| Xue, Ruizhi| Sadahira, Takuya| Hu, Hao| Wada, Koichiro| Li, Na| Liu, Chunxiao| Araki, Motoo| Xu, Abai| Huang, Peng|
Keywords Posaconazole cell cycle autophagy rhabdomyosarcoma hedgehog proteins
Published Date 2021-09-30
Publication Title American Journal of Cancer Research
Volume volume11
Issue issue9
Publisher e-Century Publishing Corporation
Start Page 4528
End Page 4540
ISSN 2156-6976
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders AJCR (c)2021 e-Century Publishing Corp.
File Version publisher
PubMed ID 34659903
Web of Science KeyUT 000707716300029
JaLCDOI 10.18926/AMO/62820
FullText URL 75_6_763.pdf
Author Iwata, Takehiro| Sadahira, Takuya| Maruyama, Yuki| Sekito, Takanori| Yoshinaga, Kasumi| Watari, Shogo| Nagao, Kentaro| Kawada, Tatsushi| Tominaga, Yusuke| Nishimura, Shingo| Takamoto, Atsushi| Sako, Tomoko| Edamura, Kohei| Kobayashi, Yasuyuki| Araki, Motoo| Ishii, Ayano| Watanabe, Masami| Watanabe, Toyohiko| Nasu, Yasutomo| Wada, Koichiro|
Abstract The aim of this ongoing trial is to evaluate the clinical efficacy and safety of sitafloxacin (STFX) 200 mg once daily (QD) for 7 days in patients with refractory genitourinary tract infections, which include recurrent or complicated cystitis, complicated pyelonephritis, bacterial prostatitis, and epididymitis. The primary endpoint is the microbiological efficacy at 5-9 days after the last administration of STFX. Recruitment began in February 2021, and the target total sample size is 92 participants.
Keywords genitourinary tract infections fluoroquinolone resistance extended-spectrum beta-lactamase
Amo Type Clinical Study Protocol
Publication Title Acta Medica Okayama
Published Date 2021-12
Volume volume75
Issue issue6
Publisher Okayama University Medical School
Start Page 763
End Page 766
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders Copyright Ⓒ 2021 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 34955548
Web of Science KeyUT 000735319800006
NAID 120007180272
JaLCDOI 10.18926/AMO/62810
FullText URL 75_6_705.pdf
Author Iwata, Takehiro| Maruyama, Yuki| Kawada, Tatsushi| Sadahira, Takuya| Katayama, Satoshi| Takamoto, Atsushi| Sako, Tomoko| Wada, Koichiro| Edamura, Kohei| Kobayashi, Yasuyuki| Araki, Motoo| Watanabe, Masami| Watanabe, Toyohiko| Nasu, Yasutomo|
Abstract Optimal neoadjuvant hormone therapy (NHT) for reducing prostate cancer (PC) patients’ prostate volume pre-brachytherapy is controversial. We evaluated the differential impact of neoadjuvant gonadotropin-releasing hormone (GnRH) antagonist versus agonist on post-brachytherapy testosterone recovery in 112 patients treated pre-brachytherapy with NHT (GnRH antagonist, n=32; GnRH agonists, n=80) (Jan. 2007-June 2019). We assessed the effects of patient characteristics and a GnRH analogue on testosterone recovery with logistic regression and a propensity score analysis (PSA). There was no significant difference in the rate of testosterone recovery to normal levels (> 300 ng/dL) between the GnRH antagonist and agonists (p=0.07). The GnRH agonists induced a significantly more rapid testosterone recovery rate at 3 months post-brachytherapy versus the GnRH antagonist (p<0.0001); there was no difference in testosterone recovery at 12 months between the GnRH antagonist/agonists (p=0.8). In the multivariate analysis, no actor was associated with testosterone recovery. In the PSA, older age and higher body mass index (BMI) were significantly associated with longer testosterone recovery. Post-brachytherapy testosterone recovery was quicker with the neoadjuvant GnRH agonists than the antagonist, and the testosterone recovery rate was significantly associated with older age and higher BMI. Long-term follow-ups are needed to determine any differential effects of GnRH analogues on the quality of life of brachytherapy-treated PC patients.
Keywords testosterone recovery GnRH antagonist GnRH agonist brachytherapy prostate cancer
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2021-12
Volume volume75
Issue issue6
Publisher Okayama University Medical School
Start Page 705
End Page 711
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders Copyright Ⓒ 2021 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 34955538
Web of Science KeyUT 000735297900006
NAID 120007180282
FullText URL fulltext.pdf
Author Lin, Wenfeng| Sun, Jingkai| Sadahira, Takuya| Xu, Naijin| Wada, Koichiro| Liu, Chunxiao| Araki, Motoo| Xu, Abai| Watanabe, Masami| Nasu, Yasutomo| Huang, Peng|
Keywords Urothelial bladder cancer doxorubicin cisplatin chemoresistance nitroxoline STAT3
Published Date 2021-07-25
Publication Title International Journal of Biological Sciences
Volume volume17
Issue issue12
Publisher Ivyspring International Publisher
Start Page 3255
End Page 3267
ISSN 1449-2288
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © The author(s).
File Version publisher
DOI 10.7150/ijbs.63125
Web of Science KeyUT 000682847000007
Related Url isVersionOf https://doi.org/10.7150/ijbs.63125
FullText URL fulltext20210721-2.pdf figure20210721-2.pdf
Author Watari, Shogo| Araki, Motoo| Wada, Koichiro| Yoshinaga, Kasumi| Maruyama, Yuki| Mitsui, Yosuke| Sadahira, Takuya| Kubota, Risa| Nishimura, Shingo| Kobayashi, Yasuyuki| Takeuchi, Hidemi| Tanabe, Katsuyuki| Kitagawa, Masashi| Morinaga, Hiroshi| Kitamura, Shinji| Sugiyama, Hitoshi| Wada, Jun| Watanabe, Masami| Watanabe, Toyohiko| Nasu, Yasutomo|
Note © 2021 Published by Elsevier Inc. This manuscript version is made available under the CC-BY-NC-ND 4.0 License. http://creativecommons.org/licenses/by-nc-nd/4.0/. This is the accepted manuscript version. The formal published version is available at [https://doi.org/10.1016/j.transproceed.2021.03.043] . |
Published Date 2021-4-28
Publication Title Transplantation Proceedings
Volume volume53
Issue issue5
Publisher Elsevier BV
Start Page 1494
End Page 1500
ISSN 0041-1345
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
File Version author
PubMed ID 33931247
DOI 10.1016/j.transproceed.2021.03.043
Web of Science KeyUT 000668604400017
Related Url isVersionOf https://doi.org/10.1016/j.transproceed.2021.03.043
FullText URL fulltext20210625-1.pdf
Author Matsuo, Toshihiko| Tanaka, Takehiro| Nakamura, Aya| Wada, Koichiro|
Keywords prostate cancer choroidal/uveal tumor choroidal/uveal metastasis radiation surgical castration complete remission hormonal therapy literature review prostate-specific antigen PSA positron emission tomography PET
Published Date 2021-06-23
Publication Title Journal of Investigative Medicine High Impact Case Reports
Volume volume8
Publisher American Federation for Medical Research
Start Page 1
End Page 8
ISSN 2324-7096
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © 2021 American Federation for Medical Research
File Version publisher
PubMed ID 34159819
NAID 120007089816
DOI 10.1177/23247096211026471
Related Url isVersionOf https://doi.org/10.1177/23247096211026471
FullText URL fulltext.pdf
Author Yoshinaga, Kasumi| Araki, Motoo| Wada, Koichiro| Sekito, Takanori| Watari, Shogo| Maruyama, Yuki| Mitsui, Yosuke| Sadahira, Takuya| Kubota, Risa| Nishimura, Shingo| Edamura, Kohei| Kobayashi, Yasuyuki| Tanabe, Katsuyuki| Takeuchi, Hidemi| Kitagawa, Masashi| Kitamura, Shinji| Wada, Jun| Watanabe, Masami| Watanabe, Toyohiko| Nasu, Yasutomo|
Keywords diabetes mellitus kidney function kidney transplantation marginal donor
Published Date 2021-06-08
Publication Title Immunity Inflammation and Disease
Publisher Wiley
ISSN 2050-4527
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © 2021 The Authors.
File Version publisher
PubMed ID 34102025
NAID 120007053366
DOI 10.1002/iid3.470
Web of Science KeyUT 000658836600001
Related Url isVersionOf https://doi.org/10.1002/iid3.470
FullText URL fulltext20210603-2.pdf
Author Matsumoto, Jun| Kotera, Yumi| Watari, Shogo| Takeuchi, Koichi| Ueki, Hideo| Koyama, Toshihiro| Wada, Koichiro| Fujiyoshi, Masachika| Nasu, Yasutomo| Ariyoshi, Noritaka|
Keywords human cytochrome P450 CYP3A renal cell carcinoma treatment outcome
Published Date 2021-5
Publication Title Anticancer Research
Volume volume41
Issue issue5
Publisher International Institute of Anticancer Research
Start Page 2511
End Page 2521
ISSN 0250-7005
NCID AA10625860
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders Copyright © 2021 by The International Institute of Anticancer Research
File Version publisher
PubMed ID 33952479
DOI 10.21873/anticanres.15029
Web of Science KeyUT 000648665800021
Related Url isVersionOf https://doi.org/10.21873/anticanres.15029
FullText URL fulltext.pdf
Author Wada, Koichiro| Araki, Motoo| Tanimoto, Ryuta| Sadahira, Takuya| Watari, Shogo| Maruyama, Yuki| Mitsui, Yosuke| Nakajima, Hirochika| Acosta, Herik| Katayama, Satoshi| Iwata, Takehiro| Nishimura, Shingo| Takamoto, Atsushi| Sako, Tomoko| Edamura, Kohei| Kobayashi, Yasuyuki| Watanabe, Masami| Watanabe, Toyohiko| Nasu, Yasutomo|
Keywords Photodynamic diagnosis 5-Aminolevulinic acid ALA-PDD Upper urinary tract urothelial carcinoma VISERA ELITE video system
Published Date 2021-03-25
Publication Title BMC urology
Volume volume21
Issue issue1
Publisher BMC
Start Page 45
ISSN 1471-2490
NCID AA12035460
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © The Author(s) 2021.
File Version publisher
PubMed ID 33765999
NAID 120007008530
DOI 10.1186/s12894-021-00819-2
Web of Science KeyUT 000632906900001
Related Url isVersionOf https://doi.org/10.1186/s12894-021-00819-2
FullText URL fulltext.pdf Fig_1.pptx Fig_2.pptx
Author Maruyama, Yuki| Araki, Motoo| Wada, Koichiro| Yoshinaga, Kasumi| Mitsui, Yosuke| Sadahira, Takuya| Nishimura, Shingo| Edamura, Kohei| Kobayashi, Yasuyuki| Watanabe, Masami| Watanabe, Toyohiko| Monga, Manoj| Nasu, Yasutomo| Kumon, Hiromi|
Keywords urothelial carcinoma urinary tract cancer ureteroscopy long-term survival renal pelvis ureter
Note This is a pre-copyedited, author-produced version of an article accepted for publication in Japanese Journal of Clinical Oncology following peer review. The version of record Long-term ureteroscopic management of upper tract urothelial carcinoma: 28-year single-centre experience, Japanese Journal of Clinical Oncology, Volume 51, Issue 1, January 2021, Pages 130–137 is available online at: https://doi.org/10.1093/jjco/hyaa132.|
Published Date 2020-7-27
Publication Title Japanese Journal of Clinical Oncology
Volume volume51
Issue issue1
Publisher Oxford University Press
Start Page 130
End Page 137
ISSN 0368-2811
NCID AA00690866
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
File Version author
PubMed ID 32715306
DOI 10.1093/jjco/hyaa132
Web of Science KeyUT 000608420900018
Related Url isVersionOf https://doi.org/10.1093/jjco/hyaa132
JaLCDOI 10.18926/AMO/54989
FullText URL 71_2_187.pdf
Author Takamoto, Atsushi| Araki, Motoo| Wada, Koichiro| Sugimoto, Morito| Kobayashi, Yasuyuki| Sasaki, Katsumi| Watanabe, Toyohiko| Nasu, Yasutomo|
Abstract We report the case of a 58-year-old Japanese man with bilateral synchronous renal cell carcinoma (RCC). The diameters of the right and left tumors were 56 and 69 mm, respectively. Both tumors were endophytic. Cryoablation with prophylactic embolization was performed for the left tumor, and 1 month later, a right open partial nephrectomy was performed. No recurrence was observed during a 16-month follow-up, and the serum creatinine level has been stable. The prognosis of bilateral synchronous RCC is better than that of dialysis patients. The novel approach of combining cryoablation and partial nephrectomy can achieve good cancer control and renal function in bilateral RCC.
Keywords cryoablation multiple renal masses nephron-sparing surgery renal cell carcinoma synchronous multiple primary
Amo Type Case Report
Publication Title Acta Medica Okayama
Published Date 2017-04
Volume volume71
Issue issue2
Publisher Okayama University Medical School
Start Page 187
End Page 190
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2017 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 28420902
JaLCDOI 10.18926/AMO/54982
FullText URL 71_2_135.pdf
Author Mori, Akihiro| Watanabe, Masami| Sadahira, Takuya| Kobayashi, Yasuyuki| Ariyoshi, Yuichi| Ueki, Hideo| Wada, Koichiro| Ochiai, Kazuhiko| Li, Shun-Ai| Nasu, Yasutomo|
Abstract The cluster of differentiation 147 (CD147), also known as EMMPRIN, is a key molecule that promotes cancer progression. We previously developed an adenoviral vector encoding a tumor suppressor REIC/Dkk-3 gene (Ad-REIC) for cancer gene therapy. The therapeutic effects are based on suppressing the growth of cancer cells, but, the underlying molecular mechanism has not been fully clarified. To elucidate this mechanism, we investigated the effects of Ad-REIC on the expression of CD147 in LNCaP prostate cancer cells. Western blotting revealed that the expression of CD147 was significantly suppressed by Ad-REIC. Ad-REIC also suppressed the cell growth of LNCaP cells. Since other researchers have demonstrated that phosphorylated mitogen-activated protein kinases (MAPKs) and c-Myc protein positively regulate the expression of CD147, we investigated the correlation between the CD147 level and the activation of MAPK and c-Myc expression. Unexpectedly, no positive correlation was observed between CD147 and its possible regulators, suggesting that another signaling pathway was involved in the downregulation of CD147. This is the first study to show the downregulation of CD147 by Ad-REIC in prostate cancer cells. At least some of the therapeutic effects of Ad-REIC may be due to the downregulation of the cancer-progression factor, CD147.
Keywords prostate cancer REIC/Dkk-3 CD147 cell growth p38 MAP kinase
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2017-04
Volume volume71
Issue issue2
Publisher Okayama University Medical School
Start Page 135
End Page 142
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2017 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 28420895
JaLCDOI 10.18926/AMO/54508
FullText URL 70_4_299.pdf
Author Wada, Koichiro| Uehara, Shinya| Ishii, Ayano| Sadahira, Takuya| Yamamoto, Masumi| Mitsuhata, Ritsuko| Takamoto , Atsushi| Araki, Motoo| Kobayashi, Yasuyuki| Watanabe, Masami| Watanabe, Toyohiko| Hotta, Katsuyuki| Nasu, Yasutomo|
Abstract Urinary tract infections (UTIs) are the most common bacterial infections in women, and many patients experience frequent recurrence. The aim of this report is to introduce an on-going prospective phase II clinical trial performed to evaluate the preventive effectiveness of Lactobacillus vaginal suppositories for prevention of recurrent cystitis. Patients enrolled in this study are administered vaginal suppositories containing the GAI 98322 strain of Lactobacillus crispatus every 2 days or 3 times a week for one year. The primary endpoint is recurrence of cystitis and the secondary endpoints are adverse events. Recruitment began in December 2013 and target sample size is 20 participants.
Keywords probiotics lactobacilli Lactobacillus crispatus urinary tract infection vaginal suppository
Amo Type Clinical Study Protocols
Publication Title Acta Medica Okayama
Published Date 2016-08
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 299
End Page 302
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549677
Web of Science KeyUT 000384748600012
JaLCDOI 10.18926/AMO/54507
FullText URL 70_4_295.pdf
Author Araki, Motoo| Wada, Koichiro| Mitsui, Yosuke| Kubota, Risa| Yoshioka, Takashi| Ariyoshi, Yuichi| Kobayashi, Yasuyuki| Kitagawa, Masashi| Tanabe, Katsuyuki| Sugiyama, Hiroshi| Wada, Jun| Watanabe, Masami| Watanabe, Toyohiko| Hotta, Katsuyuki| Nasu, Yasutomo|
Abstract Although graft survival following renal transplantation (RTx) has improved, outcomes following highrisk RTx are variable. Preexisting antibodies, including donor-specific antibodies (DSA), play an important role in graft dysfunction and survival. We have designed a study to investigate the safety and efficacy of anti-CD20 monoclonal antibodies (rituximab) in high-risk RTx recipients. Major eligibility criteria include: 1) major and minor ABO blood group mismatch, 2) positive DSA. Thirty-five patients will receive 200 mg/body of rituximab. The primary endpoint is the incidence of B cell depletion. This study will clarify whether rituximab is efficacious in improving graft survival in high-risk RTx recipients.
Keywords end-stage renal disease immunosuppression kidney transplantation
Amo Type Clinical Study Protocols
Publication Title Acta Medica Okayama
Published Date 2016-08
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 295
End Page 297
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549676
Web of Science KeyUT 000384748600011
JaLCDOI 10.18926/AMO/54423
FullText URL 70_3_223.pdf
Author Ebara, Shin| Kobayashi, Yasuyuki| Sasaki, Katsumi| Araki, Motoo| Sugimoto, Morito| Wada, Koichirou| Fujio, Kei| Takamoto, Atsushi| Watanabe, Toyohiko| Yanai, Hiroyuki| Nasu, Yasutomo|
Abstract The present case report describes a case of recurrent and advanced urachal carcinoma including neuroendocrine features with iliac bone metastasis after partial cystectomy and adjuvant chemotherapy consisting of irinotecan and cisplatin in a 32-year-old man. He received gemcitabine/cisplatin/ paclitaxel (GCP) combination chemotherapy, consisting of gemcitabin (1,000mg/m2) on day 1, 8, cisplatin (70mg/m2) on day 1, and paclitaxel (80mg/m2) on day 1 and 8. After three cycles of chemotherapy, PET-CT showed complete regression of the disease. So the patient underwent total cystourethrectomy, and histological examination showed an almost complete pathological response. External beam radiation therapy was also given to the ileac bone metastasis regions. However, PET-CT taken 17 months after the external beam radiation showed multiple lung metastases. He received GCP chemotherapy again, which resulted in a complete response again after three cycles of chemotherapy. This is the first report on GCP chemotherapy used not only as a salvage chemotherapy but also as a rechallenge regimen for metastatic urachal cancer including a neuroendocrine component.
Amo Type Case Report
Publication Title Acta Medica Okayama
Published Date 2016-06
Volume volume70
Issue issue3
Publisher Okayama University Medical School
Start Page 223
End Page 227
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27339213
Web of Science KeyUT 000379406100011
JaLCDOI 10.18926/AMO/54414
FullText URL 70_3_159.pdf
Author Yoshioka, Takashi| Otsuki, Hideo| Uehara, Shinya| Shimizu, Toshihiro| Murao, Wataru| Fujio, Koji| Fujio, Kei| Wada, Koichiro| Araki, Motoo| Nasu, Yasutomo|
Abstract Upper urinary tract calculi are common; however, there is no recommended treatment selection for elderly patients. Ureteroscopic holmium laser lithotripsy (URS lithotripsy) is minimally invasive, and it provides a high stone-free rate (SFR) treatment for upper urinary tract calculi. Here, we retrospectively evaluated the surgical outcomes of URS lithotripsy after dividing the 189 cases into 3 groups by patient age: the ʻ<65 groupʼ (<65 years old, n=108), the ʻ65-74 groupʼ (65-74 years old, n=42), and the ʻ 75 groupʼ ( 75 years old, n=39). The patientsʼ characteristics, stone status, and perioperative outcomes were assessed. The 65-74 group and the 75 group had a significantly higher prevalence of hypertension compared to the<65 group. Compared to the<65 group, the 65-74 group had a significantly higher prevalence of hyperlipidemia, and the 75 group had significantly higher the American Society of Anesthesiologists (ASA) scores. Despite these preoperative risk factors, SFR and postoperative pyelonephritis in the 65-74 group and the 75 group were similar to those of the<65 group. In conclusion, URS lithotripsy is the preferred treatment for upper urinary tract calculi, even for elderly patients who have multiple preoperative risk factors.
Keywords upper urinary tract calculi ureteroscopy (URS) holmium laser lithotripsy elderly patients stone-free rate (SFR)
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2016-06
Volume volume70
Issue issue3
Publisher Okayama University Medical School
Start Page 159
End Page 166
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27339204
Web of Science KeyUT 000379406100002